Treatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DAM Study)

Figures & data

Table 1 Baseline Demographic Characteristics of Both Treatment Groups

Parameter	Group 1 (n=15)	Group 2 (n=15)	Overall (n=30)
Mean Age (years)	58.8	59.8	59.3
Range of Ages (years)	37–72	37–77	37–77
SD of Ages (years)	9.28	9.47	9.23
Number of Males	7	10	17
Number of Females	8	5	13
Number of OD Eyes Enrolled	9	9	18
Number of OS Eyes Enrolled	6	6	12

Abbreviations: SD, standard deviation; OD, oculus dexter; OS, oculus sinister.

Table 2 Specifications of the Micropulse Laser Used for Treating Group 2

Laser Aspect	Specification
Size of laser spot	200 μm
Duration of laser pockets	20 ms
Micropulse duty cycle	10%
Laser energy	Micropulsed laser will be used to create light (barely visible) test burns outside the macular area (starting at 100 mw with upward titration). The laser will then be decreased to 90% of that of the test burns. The final laser spots should not be visible.
Delivery pattern	3 x 3 pattern mode (confluent spots) over the entire macular area including the foveal centre. Non-pattern repeat mode with overlapping burns is also permitted.
Wavelength	532 nm
Manufacturer	Quantel (SupraScan 532)

Table 3 Follow-Up and Treatment Schedule for Both Groups of Patients

Week #	0	4	8	12	16	20	24	28	32	36	40	44	48
BCVA, exam, FP, FAF, OCT; study eye	+	+	+	+	+	+	+	+	+	+	+	+	+
BCVA, exam, FP, FAF, OCT; non-study eye	+						+						+
Aflibercept Injection	+	±	±	±	±	±	±	±	±	±	±	±	±
MP/Sham laser	+			±	±	±	±	±	±	±	±	±	±

Abbreviations: BCVA, best corrected visual acuity; FP, fundus photography; FAF, fundus autofluorescence; OCT, optical coherence tomography; MP, micropulse.

Figure 1 Average best corrected visual acuity of treated eyes in both groups.

Figure 2 Average central macular thickness of treated eyes in both groups.